Drug intelligence / Profile preview

PLEB001

Development stage: Unknown
Lead developer: Bosheng Excellence Biotechnology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

PLEB001 is a cell therapy product consisting of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). It is being developed by The First Medical Center of the PLA General Hospital for the treatment of grade II to IV steroid-refractory acute graft-versus-host disease (aGVHD). Mesenchymal stem cells are characterized by their ability to modulate the immune system, primarily through the inhibition of T-cell proliferation, the induction of regulatory T cells, and the alteration of cytokine secretion profiles. PLEB001 aims to reduce the severe systemic inflammation and tissue damage associated with aGVHD in patients who have failed to respond to standard corticosteroid therapy.

Other names: hUC-MSC PLEB001human umbilical cord-derived mesenchymal stem cells PLEB001

Beyond the preview

Go deeper on PLEB001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLEB001.

Explore the full profile